Opens in a new tab

Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 18 March 2024)

Date18 March 2024
CourtCFI
DivisionMunich (DE) Central Division - Section
Type of actionRevocation Action
Case number(s)UPC_CFI_80/2023
Registry referenceACT_465342/2023 · ORD_598256/2023 · UPC_CFI_80/2023
PartiesASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE v. Osaka University, Healios K.K

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By an order of 18 March 2024 following the interim conference (UPC_CFI_80/2023, ACT_465342/2023, order no. 598256), the judge-rapporteur of panel 1 of the Munich Central Division (A. Kupecz), in the revocation action on EP 3 056 564 brought by Astellas Institute for Regenerative Medicine against Healios K.K and Osaka University, admitted document D21, set the value of the proceedings at EUR 4,000,000 for the scale of ceilings on recoverable costs and confirmed the oral hearing for 26 June 2024.

Question

How does the judge-rapporteur deal, at the close of the interim conference, with the admission of a late document, the value of the proceedings and the timetable for costs submissions?

Decision

Document D21 was admitted, on condition that the Defendant may file a succinct reply, possibly with a short reply expert report, by 11 April 2024, strictly limited to the points raised. After discussion with the parties, the value of the proceedings was set at EUR 4,000,000 (Rule 104(j) in connection with Rule 152.3 RoP). The judge-rapporteur noted that the scale sets a ceiling on recoverable costs rather than an amount owed, that under Art. 69 UPCA reasonable and proportionate costs are borne by the unsuccessful party, and that the Court will in principle respect an agreement between the parties on their amount. Costs exhibits may be filed until 11 June 2024, with an update by noon CET on 24 June 2024.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 69
Rules of Procedure
Rules 9, 28, 104(j), 105.1, 105.5, 106, 108, 152.3 and 333

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Revocation action.

Publications by Matthieu Dhenne: G 1/25, Take Three: Anything You Leave in the Description May Be Used Against You (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_80/2023 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 11 October 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_80/2023, 11 October 2023) Revocation Action · UPC_CFI_80/2023

    Le mémoire en défense à l'action en nullité est réputé signifié à la demanderesse le 29 septembre 2023, le délai de réponse à la demande de sursis sera fixé par une ordonnance distincte.

  2. 17 November 2023 Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 17 November 2023) Revocation Action · UPC_CFI_80/2023

    L'annexe confidentielle n'est accessible qu'aux représentants des défenderesses et à trois personnes physiques désignées, dont un conseil externe. Elle est soustraite à l'accès des tiers et l'appel est autorisé.

  3. 20 November 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 20 November 2023) Revocation Action · UPC_CFI_80/2023

    Le sursis à statuer sur l'action en nullité est refusé : une décision de la division d'opposition proche mais susceptible de recours n'emporte pas, à ce stade, une décision rapide justifiant la suspension, l'appel est autorisé.

  4. 18 March 2024 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 18 March 2024) Revocation Action · UPC_CFI_80/2023

What the record states

Nature of the act
Revocation Action
Outcome (Dhenne Avocats summary)
Le document D21 est admis sous réserve d'une réponse de la défenderesse avant le 11 avril 2024, la valeur du litige est fixée à 4 000 000 euros et l'audience confirmée au 26 juin 2024.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.